Brief report : High MET overexpression does not predict the presence of MET exon 14 splice mutations in NSCLC : results from the IFCT Predict.amm study.

Simon Baldacci,Martin Figeac,Martine Antoine,Clotilde Descarpentries,Zoulika Kherrouche,Philippe Jamme,Marie-Christine Copin,David Tulasne,Isabelle Nanni,Michèle Beau-Faller,Samia Melaabi,Guénaëlle Levallet,Elisabeth Quoix,Denis Moro-Sibilot,Sylvie Friard,Pascale Missy,Fabrice Barlesi,Jacques Cadranel,Alexis B Cortot

Journal of Thoracic Oncology（2020）

引用 20|浏览69

暂无评分

摘要

The rate of METex14 mutations in NSCLC with high MET overexpression was similar to that found in unselected NSCLC. Moreover, we observed a high frequency of driver alterations in other oncogenes. Consequently these findings do not support the use of MET IHC as a surrogate marker for METex14 mutations.

查看译文

关键词

NSCLC,MET,Receptor tyrosine kinase,Next-generation sequencing,Immunohistochemistry

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要